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Abstract
Background: To develop Singapore Chinese and English versions of the Psoriatic Arthritis Quality of Life (PsAQoL)
scale that were equivalent to and met the same psychometric and acceptability standards as the original UK measure.
Methods: Translation of the original PsAQoL into contextualised English and Chinese versions for use in Singapore was
performed by professional and lay translation panels. Ten Chinese speaking and ten English speaking local patients
were interviewed to assess face and content validity. Psoriatic arthritis (PsA) patients (either Chinese or English
speaking) fulfilling the Classification criteria of Psoriatic Arthritis were then invited to participate in a validation survey.
Clinical variables, the Health Assessment Questionnaire (HAQ) and the Medical Outcome Short-form 36 (SF-36) were
used as comparator instruments for convergent validity. A separate sample of PsA patients were invited to participate
in a test-retest postal study, with two weeks between administrations.
Results: The validation sample included 98 patients (51 % men) with a mean (SD) age of 51.5 (13.8) years. The PsAQoL
had excellent internal consistency (Cronbach’s α = 0.92) and scores on the measure were moderately correlated with
health status measures (pain, HAQ score, SF-36 scores) and patient and physician global assessments. The scale was
able to distinguish between groups with active or inactive disease assessed by composite scores, HAQ and minimal
disease activity. Test–retest reliability was excellent (r = 0.92).
Conclusions: This study provides evidence that the adapted English and Chinese versions of the PsAQoL can be used
in clinical studies with PsA patients in Singapore.
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Background
Psoriatic arthritis (PsA) is a serious condition that can lead
to joint destruction, disability and impaired quality of life
(QoL) [1–4]. QoL has been identified as one of the core
domains that are important for clinical and observational
trials in PsA by the Group for Research and Assessment
in Psoriasis and Psoriatic Arthritis (GRAPPA) and has
been subsequently endorsed by the Society of Outcome
Measures in Rheumatology (OMERACT) [5].
A number of measures have been used to assess
patient-reported outcomes (PROs) in PsA. Most of these
focus on the symptoms and functional limitations
experienced by patients [6–8]. Such measures assess
health status rather than QoL. A widely applied model of
QoL in health research is the needs-based model [9]. This
defines QoL as the extent to which a patient is able to
meet his or her fundamental human needs. The model
has been applied in the development of over 30 disease-
specific PROs, including measures for rheumatoid arthritis
[10], ankylosing spondylitis [11], systemic lupus erythema-
tosus [12], osteoarthritis [13] and PsA. These measures
have been widely used in multinational clinical trials.
The Psoriatic Arthritis Quality of Life (PsAQoL) scale
was the first patient-derived disease-specific instrument
for measuring outcome in PsA [14]. It complies with the
US Food and Drug Administration (FDA) recommenda-
tion of using inputs elicited from patients to support la-
beling claims [15]. The PsAQoL has been adapted for
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use in several countries [16, 17] and has been used in
clinical trials in PsA [18, 19].
Singapore is a multiethnic Asian country composed of
74.1 % Chinese, 13.4 % Malay, 9.4 % Indian and 3.3 %
other ethnicities. Eighty percent of the population are
literate in English and 71 % in English and one or more
additional languages [20]. Questionnaires available in
Chinese and English languages cover 98 % of Singaporeans.
The aim of this study was to develop a version of the
PsAQoL suitable for use in Singapore. It was required to
meet the same psychometric and acceptability standards
as the original United Kingdom (UK) measure. With a
resident population of under Six million it is difficult to
justify adapting a measure for PsA into the different
languages spoken in the country. Consequently, a deci-
sion was taken to produce English and Chinese language
versions of the PsAQoL and to validate them with a
combined sample of patients.
Methods
All study protocols were approved by the SingHealth
Centralized Institutional Review Board. Prior to their
inclusion in the study, all patients gave informed consent
(CIRB 2012/696/E).
Translation of the PsAQoL
The PsAQoL was translated into Singapore Chinese and
English using the dual-panel methodology, which is used
in the adaptation of new language versions of all needs-
based QoL measures [21]. Research has shown that the
dual-panel methodology produces translations that are
more acceptable to patients than the standard forward-
backward methodology [22]. The approach involves
conducting two independent translation panels; a bilin-
gual panel followed by a lay panel. The purpose of the
bilingual panel is to produce an initial translation of the
questionnaire into the target language. This version is then
presented to a lay panel of monolingual lindividuals of
average educational level who assess the items and instruc-
tions for comprehensiveness and ‘naturalness’ of language.
As the original PsAQoL is in English, only a lay panel was
necessary for the Singapore English adaptation, to ensure
that the wording of the items was appropriate for local pa-
tients. All panels were led by the same moderator.
Validation of the new language versions
PsA patients fulfilling the Classification criteria of Psori-
atic Arthritis (CASPAR) [23] were recruited from a PsA
outpatient clinic of a tertiary hospital.
Cognitive debriefing interviews: field testing for face and
content validity
Cognitive debriefing interviews (CDIs) were conducted
with both Singapore Chinese speaking and Singapore
English speaking PsA patients to test the acceptability,
relevance and comprehensiveness of the questionnaire
items and instructions. Questionnaires were completed in
the presence of an interviewer who made note of any obvi-
ous difficulties or hesitation over particular items. Patients
were then asked whether they considered the items rele-
vant, applicable and comprehensible and if any important
aspects of their experience of PsA had been excluded.
Psychometric validation
Given the small number of PsA patients in Singapore it
was decided to validate the translations with combined
samples of Singapore Chinese and English speakers.
Two surveys were conducted. The first was a cross-
sectional study to determine the internal consistency,
convergent validity and known-group validity of the
PsAQoL. The second was a postal survey conducted
with a separate sample of PsA patients to assess the test-
retest reliability of the Singaporean PsAQoL.
Cross-sectional study
Patients were examined by a rheumatologist for joint
and skin condition and Physical Global Assessment
(PhGA) was recorded. PsA disease activity was assessed
using the clinical Disease Activity Index for Psoriatic
Arthritis (cDAPSA) [24], the Composite Psoriatic
Disease Activity Index (CPDAI) [25] and Minimal
Disease Activity (MDA) [26]. Thresholds are available to
stratify patients into high, moderate and low disease ac-
tivity status. Patients were categorized into four disease
activity states by cDAPSA: ≤ 4 (remission); 4 to ≤ 13
(low disease activity); < 13 to ≤ 27 (moderate disease ac-
tivity) and > 27 (high disease activity). Similarly, three
disease activity categories were defined by CPDA: ≤ 3
(mild), 4 to 6 (moderate) and ≥ 7 (severe). The validity, re-
liability and sensitivity to change of these thresholds have
been demonstrated [27, 28].
Patients then completed a demographic questionnaire,
the PsAQoL (version dependent on their primary language)
and the following comparator scales described below.
PsAQoL
The PsAQoL has 20 dichotomous (True/Not true) items.
‘True’ responses are summed to create a total score.
High scores indicate poor QoL.
The health assessment questionnaire (HAQ) [29]
This measures functional limitations in arthritic disease.
It consists of 20 items covering eight categories each
with a four-point scale.
The short form health survey (SF-36) [30]
This is a generic health status instrument consisting of 36
items which form eight domains (Physical Functioning,
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Role physical, Bodily pain, General health, Vitality, Social
function, Role emotion and Mental health) and two sum-
mary scales (Physical Component Summary and Mental
Component Summary). Scores for each scale are calcu-
lated by summing the items in each domain, which are
then transformed onto a scale of 0 ‘worst health’ to 100
‘best health’. Psychometric evaluation for PsA and using
item response theory has been reported [6, 7]. Both Eng-
lish and Chinese language versions of the HAQ and SF-36
have been adapted for use in Singapore [31, 32]. The sum-
mary scales were standardized to the population mean
(SD) of 50 [10, 33].
Patient global disease activity (PGA) and perceived pain
were assessed using a 100 mm visual analogue scale.
Statistical analyses
Internal consistency measures the extent to which items in
a scale are inter-related and is assessed using Cronbach’s
alpha coefficient. A value of 0.7 or above indicates that the
items are adequately interrelated to form a scale [34].
Convergent validity is determined by assessing the level
of association between scores on one scale and those on a
comparator scale that measures the same or related con-
structs. Scores on the PsAQoL were correlated with the
clinical assessments and scores on the comparator scales
using Spearman’s rank correlation coefficients.
Known group validity is evaluated by testing the ability
of a measure to distinguish between groups of people
that are known to differ. The factors used for the present
study were HAQ score [29], cDAPSA score [24], CPDAI
[25] score and MDA [26]. Non-parametric tests for inde-
pendent samples (Mann–Whitney U test for two groups
or Kruskal-Wallis One-Way Analysis of Variance for
three or more groups) were employed.
Test-retest reliability study
The test-retest reliability of a measure is an estimate of
its reproducibility over time when no change in condi-
tion has taken place. The PsAQoL was administered to
patients on two occasions, two weeks apart. This time
period was chosen because it is unlikely that disease
status will change in two weeks, and this period is long
enough to avoid recall bias. The test-retest reliability was
assessed by correlating scores on the PsAQoL on two
different occasions using Spearman’s rank correlation
coefficients. A high correlation indicates that the instru-
ment produces low random measurement error.
Results
Translation of the PsAQoL questionnaire
All three translation panels (Chinese bilingual, Chinese
lay and English lay) consisted of five participants (two
males, three females) aged from 23–72 years. For the
Chinese language version, the bilingual panel found the
items and instructions straightforward and easy to trans-
late. None of the items required extended discussion.
The Chinese lay panel agreed with most translations
provided by the bilingual panel, with the exception of
seven items. For example, the item ‘I have to push myself
to do things’ was translated as ‘daily household chores’ by
the bilingual panel. However, the lay panel thought this
may only refer to housework for women and so the item
was changed to mean ‘do chores’ in the house.
The Singapore English lay panel found the PsAQoL to
be easy to adapt. However, for the item ‘It puts a strain
on my personal relationships’, the phrase ‘puts a strain’
was thought to be too difficult for patients to under-
stand. Consensus could not be reached on whether to
use ‘affects’ or ‘puts stress on’. Consequently, both
versions were assessed in the CDIs.
Cognitive debriefing interviews: assessment of face and
content validity
CDIs were conducted with ten English speaking and ten
Chinese speaking PsA patients. Ten men and ten women
participated, aged between 29 and 61 years. The mean
time taken to complete the questionnaire was 2.8 min.
Overall, patients considered the items and instructions
to be clear and easy to understand. There were no
particular items that stood out as being awkwardly
worded or difficult to understand.
Psychometric validation
Cross-sectional study
Ninety-eight PsA patients took part in the cross-
sectional study. Table 1 shows demographic and disease
information for the sample. Clinical markers and de-
scriptive statistics for the questionnaires are shown in
Table 2. The mean (SD) scores for PsAQoL was 4.5
(5.2). Cronbach’s alpha coefficient for the PsAQoL was
0.92, indicating adequate inter-relatedness of items.
Table 3 shows correlations between PsAQoL scores with
HAQ scores, SF-36 section scores and various markers
of disease activity. PsAQoL scores correlated moderately
with the Social functioning, Vitality and General health
sections of the SF-36, as well as with HAQ scores and
CPDAI, suggesting the importance of these factors to
the QoL of PsA patients. There was a very low correl-
ation between PsAQoL scores and two clinical markers;
psoriasis area and severity index (PASI) and swollen
joint count, suggesting that these have little influence on
QoLin PsA.
Figure 1 shows mean PsAQoL scores grouped by
HAQ score, cDAPSA score, CPDAI score and MDA.
Disease activity measured by cDAPSA was dichotomized
into high (moderate and high) versus low disease activity
(remission and low disease activity). Due to the distribution
of responses to the item. Significant differences were found
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Table 1 Demographic and diseaseinformation of PsA patients
(n = 98) in the cross-sectional study
Age Years
Mean (SD) 51.5 (13.8)
Duration of PsA
Mean (SD) 5.5 (8.4)
Duration of Psoriasis


























Low disease activity 47 48.0
Moderate disease activity 22 22.4







Minimal Disease Activity 38 38.2
PsA psoriatic arthritis, cDAPSA clinical disease activity in psoriatic arthritis score,
CPDAI composite psoriatic disease activity index
cDAPSA: ≤ 4 (remission); 4–≤ 13 (low disease activity); < 13–≤ 27 (moderate
disease activity) and > 27 (high disease activity)
CPDAI: ≤ 3 (mild), 4–6 (moderate) and ≥ 7 (severe)
Table 2 Clinical markers in the Cross-sectional study (n = 98)
Mean (SD)
Clinically damaged joint count (0–68) 5.0 (9.3)
Tender joint count (0–68) 2.9 (4.0)
Swollen joint count (0–66) 2.0 (2.7)
Dactylitis count (0–20) 0.8 (1.4)
Leeds Enthesitis Index (0–6) 0.3 (0.6)
PASI (0–72) 3.3 (6.0)
Pain (0–100) 33.4 (25.9)
Patient Global Assessment (0–100) 33.1 (23.5)
Physician Global Assessment (0–100) 2.9 (1.8)
ESR, mm/h 26.1 (21.6)
cDAPSA (0–154) 11.5 (9.3)
CPDAI (0–15) 5.1 (3.0)
HAQ (0–3) 0.4 (0.6)
PASI psoriasis area and severity index, ESR erythrocyte sedimentation rate, HAQ
Health Assessment Questionnaire, cDAPSA clinical Disease activity in psoriatic
arthritis score, CPDAI composite psoriatic disease activity index
Table 3 Association between PsAQoL scores and measures of
disease activity and health status
PsAQoL
Pain 0.51*
Tender joint count 0.35*
Swollen joint count 0.16
PASI 0.10
Patient global assessment 0.47*













Physical Component Summary −0.51*
Mental Component Summary −0.62*
*p < 0.0001
PASI psoriasis area and severity index, cDAPSA clinical Disease activity in
psoriatic arthritis score, CPDAI composite psoriatic disease activity index, HAQ
Health Assessment Questionnaire, SF36 Medical Outcome Short Form 36
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between patients grouped by these factors, demonstrating
the ability of the PsAQoL to distinguish between subgroups
of patients (all p-values < 0.0001).
Test-retest reliability study
A separate sample of 38 PsA patients completed the
PsAQoL on two separate occasions, approximately two
weeks apart. The sample consisted of 17 (44.7 %) men
and 21 (55.3 %) women, with a mean (SD) age of 53.9
(11.5) years. Twenty (52.6 %) patients completed the
Singapore Chinese version and 18 (47.4 %) completed
the English version. The mean (SD) PsAQoL scores at
baseline and week two were 2.7 (4.2) and 2.4 (4.4),
respectively. The Spearman’s rank correlation coeffi-
cienct was 0.92, indicating the excellent reproducibility
of the instrument. This means that the PsAQoL has a
very low level of error measurement (6 %).
Discussion
The Singapore Chinese and English versions the
PsAQoL were translated and culturally adapted to
make them suitable for use in Singapore and were
found to be of a comparable quality to the original
UK instrument. Patients found the measure to be
relevant, understandable and easy to complete in only
a few minutes. Good internal consistency, reproduci-
bility and construct validity were demonstrated. The
Singapore PsAQoL was able to distinguish between
groups that differed by PsA activity level, remission
and functional status.
The PsAQoL is the first PsA-specific instrument for
measuring QoL and has been adapted for use in 48
languages [16, 17]. This is the first study to translate and
adapt the PsAQoL into Chinese. While spoken Chinese
has many dialects, written Chinese is in the same
format. Consequently, disparate dialect groups are able
to communicate through writing [35]. As Chinese is
spoken by nearly 1.3 billion people (approximately 16 %
of the world's population) [36], the adaptation of
PsAQoL into Chinese will greatly increase the reach of
the instrument for the measurement of QoL in PsA
patients. The usage of specific Chinese words may vary
among Chinese speakers in different geographic region,
further adaptations in different region could be achieved
via patient debriefing sessions.
In this study, we simultaneously adapted the PsAQoL
into Singapore English and Singapore Chinese. English is
the official language in Singapore, and most people in
Singapore are bilingual in at least two languages [20]. In
daily clinical practice and clinical trials in the local environ-
ment, patients are allowed to choose their own language of
choice for PROs. Therefore, we think the simultaneous
validation process is practical and appropriate to the local
setting. Ideally, the absence of bias from languages should
be demonstrated by the application of Rasch analysis but
this requires a larger sample size.
PsAQoL scores in the present study were low com-
pared to scores in the PsAQoL development study in the
UK [14] but similar to those found in the Swedish and
Dutch studies [16, 17]. In all adaptation studies, 20–30 %
of patients scored the minimum and between one and two
percent scored the maximum. The low scores on the
PsAQoL in this study probably reflect the relatively mild
disease in the sample studied.
The main limitation of the study is the small sample
size, which reflects the size of the Singapore population.
This prevented an investigation of the comparability of
the performance of the Chinese and English versions.
Versions of measures are easily adapted from UK
English to other countries where English is spoken
[16, 17] and there is also the potential to combine
the Chinese speaking population in Singapore from
that in other countries. This would then allow the
performance of the two language versions to be com-
pared. Secondly, we stratified disease activity using
patient-reported instruments, which may be affected
by comorbidities such as depression and fibromyalgia.
Instruments that incorporate C-reactive protein
(CRP), like (PASDAS) [37] and DAPSA may reflect
disease activity more objectively. However, as CRP
was not included as a routine test in the clinic at the
initiation of the study, only 30 % of patients could
have a PASDAS and DAPSA score, and therefore not








        L        H
           HAQ
           (P<0.0001)
        L        H
          cDAPSA
          (P<0.0001)
             L        M        H
          CPDAI
          (P<0.0001)
            Yes     No
              MDA






Fig. 1 Mean PsAQoL scores stratified by functional limitation or
disease activity. HAQ = health assessment questionnaire;
cDAPSA = clinical disease activity in psoriatic arthritis score;
CPDAI = composite psoriatic disease activity index; MDA =minimal
disease activity. L = Low disease activity. M =moderate disease activity.
H = high disease activity
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study was not designed to assess the sensitivity to
change of the PsAQoL.
Conclusions
In conclusion, the present study showed that the
Singapore Chinese and English versions of the
PsAQoL are valid and reliable instruments when used
with combined samples of PsA patients who speak ei-
ther of these languages. Patients found the instrument
relevant to their perspective, easy to understand and
complete and easy to administer. The study provides
evidence that these versions of PsAQoL can be used
in clinical and observational studies for PsA patients
in Singapore.
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